Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 120 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Adv Mater, 2018, 30(43):e1801621

PubMed: 30203567 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(5):650-664

PubMed: 29100014 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):238-250

PubMed: 30664790 ( click the link to review the publication )

Nat Commun, 2019, 10(1):620

PubMed: 30728358 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0441-3

PubMed: 31645676 ( click the link to review the publication )

Cell Death Differ, 2019, 26(11):2300-2313

PubMed: 30778200 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766723 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )
Cells, 2019, 8(7)

PubMed: 31295851 ( click the link to review the publication )

Cancer Biomark, 2019, 10.3233/CBM-190460

PubMed: 31683459 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(46):17471-17486

PubMed: 31594861 ( click the link to review the publication )

J Biol Chem, 2019, 294(20):8161-8170

PubMed: 30940730 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010732

PubMed: 31628188 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(6):711-719

PubMed: 31585985 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2019, 183:110396

PubMed: 31394424 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

AAPS PharmSciTech, 2019, 20(5):198

PubMed: 31127389 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(10):152606

PubMed: 31500928 ( click the link to review the publication )

Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )
Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

World J Clin Oncol, 2019, 10(6):222-233

PubMed: 31367531 ( click the link to review the publication )

Oncotarget, 2019, 10(38):3667-3680

PubMed: 31217901 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4116

PubMed: 30297712 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Control Release, 2018, 283:223-234

PubMed: 29864473 ( click the link to review the publication )

Cancer Lett, 2018, 420:60-71

PubMed: 29408653 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

J Clin Med, 2018, 7(12)

PubMed: 30477228 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(2):489-504

PubMed: 29794416 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(5):2046-2060

PubMed: 30099455 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(10)

PubMed: 30326563 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )
Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Int J Med Sci, 2018, 15(7):738-747

PubMed: 29910679 ( click the link to review the publication )

DNA Repair (Amst), 2018, 63:1-9

PubMed: 29358095 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Oncotarget, 2017, 9(1):249-267

PubMed: 29416611 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )
Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(12):1240-1252

PubMed: 27791595 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41811-41824

PubMed: 27248820 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

J Control Release, 2015, 220(Pt B):727-37

PubMed: 26390807 ( click the link to review the publication )

Environ Sci Technol, 2015, 49(6):3575-83

PubMed: 25695909 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(10):1373-87

PubMed: 26276035 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2750-8

PubMed: 24062531 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	M2DCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC0UW5SUUN3ME2wMlAxODJ6NzFOwG0>	NEX6d4VUSU6JRWK=
LC-2-ad	M3P0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37qTmlEPTB;MD6wNFA{OTdizszN	NWHl[mZqW0GQR1XS
RL95-2	M2\Oemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3W4XmlEPTB;MD6wNFA3PjhizszN	M2HjTXNCVkeHUh?=
MZ1-PC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMECwO\|I6KM7:TR?=	NWLueFI6W0GQR1XS
TE-8	M2WzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDKSZJ3UUN3ME2wMlAxOTF5IN88US=>	NFLq[2NUSU6JRWK=
SW954	NX[wUGpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DoSGlEPTB;MD6wNFEyQSEQvF2=	M1v1WXNCVkeHUh?=
TE-11	M3PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfTUWpFUUN3ME2wMlAxOTJ\|IN88US=>	M3zUOXNCVkeHUh?=
PSN1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnUeXpIUUN3ME2wMlAxOTNizszN	NX\yV25mW0GQR1XS
MOLT-4	NVy5W2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXkTWM2OD1yLkCwNVQ6KM7:TR?=	MXjTRW5ITVJ?
697	M1PsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE[ze2dKSzVyPUCuNFAyPSEQvF2=	NXe0T2xkW0GQR1XS
ETK-1	NGT5[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMECxOVIh\|ryP	M3;1XHNCVkeHUh?=
TE-10	NHfnU\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMECxOVQh\|ryP	NGjpV4JUSU6JRWK=
HUTU-80	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHsTWM2OD1yLkCwNVY5KM7:TR?=	M{fH[HNCVkeHUh?=
NTERA-S-cl-D1	M{PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvafYpZUUN3ME2wMlAxOjB7IN88US=>	NWftPJpJW0GQR1XS
MFH-ino	NIHCc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jwdWlEPTB;MD6wNFI3QCEQvF2=	NUDuZYF[W0GQR1XS
IA-LM	M2X0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMECyPEDPxE1?	NXTKVY1OW0GQR1XS
MC116	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzHSXFKSzVyPUCuNFAzQDlizszN	NGP5UXFUSU6JRWK=
RKO	NXjJVlNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMECyPVgh\|ryP	MUXTRW5ITVJ?
MRK-nu-1	M3[xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLSTWM2OD1yLkCwNlk6KM7:TR?=	NVrvUoFxW0GQR1XS
VA-ES-BJ	NED6XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXCbYVKSzVyPUCuNFA{KM7:TR?=	NWTlNIdJW0GQR1XS
KALS-1	NWnBT5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMECzNFgh\|ryP	MknwV2FPT0WU
BB30-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT0dIx{UUN3ME2wMlAxOzF2IN88US=>	MUfTRW5ITVJ?
ACN	NVnEbG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknxTWM2OD1yLkCwN\|E3KM7:TR?=	MmrOV2FPT0WU
TE-9	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmniTWM2OD1yLkCwN\|I3KM7:TR?=	MkXHV2FPT0WU
SIG-M5	NVPUT4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O0XmlEPTB;MD6wNFMzPyEQvF2=	MYDTRW5ITVJ?
no-10	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHiTWM2OD1yLkCwN\|YzKM7:TR?=	MmDqV2FPT0WU
EW-1	M2LlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u4fmlEPTB;MD6wNFM4OSEQvF2=	MWHTRW5ITVJ?
SK-LMS-1	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\vNWtKSzVyPUCuNFA1ODFizszN	MlrrV2FPT0WU
GT3TKB	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PkW2lEPTB;MD6wNFQ{PCEQvF2=	NVj0dXoyW0GQR1XS
ES4	M2OxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHwNI1KSzVyPUCuNFA1PDlizszN	NIT5UIhUSU6JRWK=
IMR-5	NHH5VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEC0OUDPxE1?	MVfTRW5ITVJ?
NCI-H1648	NVrvW5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rXSGlEPTB;MD6wNFQ3QSEQvF2=	M{LscXNCVkeHUh?=
MV-4-11	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV33clF6UUN3ME2wMlAxPDd3IN88US=>	M{nWOHNCVkeHUh?=
SK-UT-1	NWmxTYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoOyTWM2OD1yLkCwOFgh\|ryP	MWPTRW5ITVJ?
NB13	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXWTWM2OD1yLkCwOFkyKM7:TR?=	M1;IVXNCVkeHUh?=
DJM-1	M2PodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzydVg3UUN3ME2wMlAxPTNizszN	M3j3b3NCVkeHUh?=
ES8	NV;GUnVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELZdlhKSzVyPUCuNFA2OzhizszN	NFS0SlhUSU6JRWK=
TE-6	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMEC1O{DPxE1?	NW\HTIxTW0GQR1XS
KS-1	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHPbGpKSzVyPUCuNFA2QDJizszN	M3TTNXNCVkeHUh?=
TE-1	NHLSUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LlVWlEPTB;MD6wNFYxPiEQvF2=	NF64cHRUSU6JRWK=
ATN-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEC2NFkh\|ryP	NGDmcWVUSU6JRWK=
A4-Fuk	M334[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\2N4FlUUN3ME2wMlAxPjFzIN88US=>	MmnaV2FPT0WU
ALL-PO	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDmOFRKSzVyPUCuNFA3OyEQvF2=	M4jR[3NCVkeHUh?=
BE-13	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkD5TWM2OD1yLkCwOlM3KM7:TR?=	MmrrV2FPT0WU
KM12	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rRTWlEPTB;MD6wNFY{PyEQvF2=	M2nFUXNCVkeHUh?=
NOS-1	NXjoXWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLJTWM2OD1yLkCwOlUh\|ryP	MmnqV2FPT0WU
SW962	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrSS\|VKSzVyPUCuNFA3PjJizszN	NIDxTZlUSU6JRWK=
OCUB-M	NXL0eXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPLTWM2OD1yLkCwOlYzKM7:TR?=	M{S0bHNCVkeHUh?=
NCI-H510A	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS0WoZUUUN3ME2wMlAxPjZ3IN88US=>	NWPr[WZYW0GQR1XS
EW-16	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjqPYhKSzVyPUCuNFA3QTRizszN	MlXsV2FPT0WU
KGN	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;EbXVKSzVyPUCuNFA4OTJizszN	NFHsNWFUSU6JRWK=
LS-411N	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEC3NVch\|ryP	MVPTRW5ITVJ?
Becker	NU\hUmJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGqzPIpKSzVyPUCuNFA4OiEQvF2=	NYnvO5I1W0GQR1XS
HC-1	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMEC3NlEh\|ryP	MmrLV2FPT0WU
CESS	NHPhWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP4XnVKSzVyPUCuNFA4OzdizszN	MUjTRW5ITVJ?
KURAMOCHI	NEX4W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnziTWM2OD1yLkCwO\|Q5KM7:TR?=	M{Po[nNCVkeHUh?=
TGBC24TKB	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrXbldKSzVyPUCuNFA4PTJizszN	NW\UdFNUW0GQR1XS
SW982	NUDLUZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEC3OlYh\|ryP	NWXhd5E3W0GQR1XS
HCE-4	NHf5OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnyTWM2OD1yLkCwO\|Y4KM7:TR?=	NIfKbIVUSU6JRWK=
LOUCY	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrLWZZKSzVyPUCuNFA4PzVizszN	NHzTfnVUSU6JRWK=
8-MG-BA	NXi1OXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYe5UJF1UUN3ME2wMlAxPzl4IN88US=>	MV7TRW5ITVJ?
HT-144	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvo[G9tUUN3ME2wMlAxQCEQvF2=	M32wTHNCVkeHUh?=
LXF-289	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPSSHJKSzVyPUCuNFA5OThizszN	NIfIO4NUSU6JRWK=
RS4-11	M2TFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rGOWlEPTB;MD6wNFg{PiEQvF2=	MVfTRW5ITVJ?
DEL	NGP2d\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HKbmlEPTB;MD6wNFg1PSEQvF2=	NH;PVI1USU6JRWK=
OCI-AML2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLqNXhKSzVyPUCuNFA5PTJizszN	NEmzUZBUSU6JRWK=
CCRF-CEM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoS2TWM2OD1yLkCwPFcyKM7:TR?=	M1KyXnNCVkeHUh?=
A388	M1nvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMEC4O\|Qh\|ryP	M2nWW3NCVkeHUh?=
KNS-42	M1rhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnqPVBKSzVyPUCuNFA5QTFizszN	MmXuV2FPT0WU
OVCAR-4	M3rJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{GwdWlEPTB;MD6wNFkxPCEQvF2=	Mm\0V2FPT0WU
NCI-H1355	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPkTWM2OD1yLkCwPVE1KM7:TR?=	NIizNmRUSU6JRWK=
BL-70	NV3PbZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPHNGpKSzVyPUCuNFA6OyEQvF2=	NVPXZXJkW0GQR1XS
BL-41	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e0b2lEPTB;MD6wNFk{PCEQvF2=	MoiyV2FPT0WU
A101D	NU\ORWFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmi0TWM2OD1yLkCwPVYh\|ryP	NFjjRnNUSU6JRWK=
HL-60	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mli4TWM2OD1yLkCwPVY3KM7:TR?=	NUjsc49[W0GQR1XS
COR-L279	M4S4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rFbGlEPTB;MD6wNFk6QSEQvF2=	M{O2UHNCVkeHUh?=
NCI-SNU-16	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHuxS2xKSzVyPUCuNFExODhizszN	MlrVV2FPT0WU
Calu-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXaWWRFUUN3ME2wMlAyODF{IN88US=>	MVvTRW5ITVJ?
SR	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3pcHFyUUN3ME2wMlAyODJ4IN88US=>	MX3TRW5ITVJ?
QIMR-WIL	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP6SppKUUN3ME2wMlAyODN\|IN88US=>	MmrSV2FPT0WU
LB647-SCLC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMEGwOVEh\|ryP	NFrxdZVUSU6JRWK=
RPMI-8226	NWi1SWxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\KVHdKSzVyPUCuNFEyODJizszN	NH[0fJhUSU6JRWK=
SK-PN-DW	M1LTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C3eWlEPTB;MD6wNVEyOiEQvF2=	NVfBZ4NHW0GQR1XS
SF268	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHNZ3FqUUN3ME2wMlAyOTVzIN88US=>	MW\TRW5ITVJ?
HD-MY-Z	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jqSWlEPTB;MD6wNVE3OyEQvF2=	MnPqV2FPT0WU
DOHH-2	M{C3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLjcFZGUUN3ME2wMlAyOjB\|IN88US=>	NV\TWFduW0GQR1XS
SCC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\keGhKSzVyPUCuNFEzODRizszN	MVjTRW5ITVJ?
ST486	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEGyNFQh\|ryP	M{jL[3NCVkeHUh?=
NALM-6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\DWHpXUUN3ME2wMlAyOjF2IN88US=>	M2Hm[nNCVkeHUh?=
NCI-H1436	NWXsUpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLUc4ZzUUN3ME2wMlAyOjNzIN88US=>	MXnTRW5ITVJ?
KE-37	NHfxN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fLRWlEPTB;MD6wNVI{PCEQvF2=	Mn3vV2FPT0WU
RPMI-8402	NIDpeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrjb3cxUUN3ME2wMlAyOjV4IN88US=>	NYDWVJgxW0GQR1XS
RXF393	M1LPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoqxTWM2OD1yLkCxNlU4KM7:TR?=	MoT4V2FPT0WU
KARPAS-45	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[yfHRKSzVyPUCuNFEzPyEQvF2=	NF[5R4hUSU6JRWK=
HOP-62	NGfOeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPkSJRKSzVyPUCuNFEzPzZizszN	NG\zN3JUSU6JRWK=
ES1	M3e2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\mcG9KSzVyPUCuNFEzQDhizszN	MXHTRW5ITVJ?
L-363	NEXHUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfXO\|ZKSzVyPUCuNFE{PTFizszN	MVzTRW5ITVJ?
GI-1	M{f2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEGzO\|Mh\|ryP	NEXIVFdUSU6JRWK=
CTV-1	M4XlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\E[2lEPTB;MD6wNVQ4QCEQvF2=	NUjHV3dtW0GQR1XS
TE-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEG0PVYh\|ryP	MorOV2FPT0WU
SNU-C2B	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS4VWU4UUN3ME2wMlAyPDl4IN88US=>	MkPBV2FPT0WU
K-562	NX;ofY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jFU2lEPTB;MD6wNVUyPiEQvF2=	NH3NZ3dUSU6JRWK=
SNB75	NWfSXoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEG1OEDPxE1?	NEX0OVFUSU6JRWK=
MOLT-13	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7hdVZyUUN3ME2wMlAyPjN5IN88US=>	M3XwN3NCVkeHUh?=
LS-123	NWPPbopiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XndGlEPTB;MD6wNVY3PCEQvF2=	NWPnZ4VzW0GQR1XS
NCI-SNU-5	NUi4dIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEG3NFEh\|ryP	MV;TRW5ITVJ?
Daudi	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P5[GlEPTB;MD6wNVcxQCEQvF2=	MVnTRW5ITVJ?
A253	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ntemlEPTB;MD6wNVc{QCEQvF2=	MojlV2FPT0WU
TGBC1TKB	M2rzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfV[5N6UUN3ME2wMlAyPzV{IN88US=>	Mm\oV2FPT0WU
SJSA-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEG3Olch\|ryP	MnzrV2FPT0WU
NCCIT	M1\ncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfXS5NKSzVyPUCuNFE4PjlizszN	M3jLXHNCVkeHUh?=
NCI-H69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTZbHNKSzVyPUCuNFE4PzhizszN	M3vkc3NCVkeHUh?=
SH-4	NEjUb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3WcGs{UUN3ME2wMlAyQDl3IN88US=>	NGTFW5BUSU6JRWK=
HCC1187	M1TKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\ycmlEPTB;MD6wNVkzPCEQvF2=	MlvkV2FPT0WU
HCC1599	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFO0clNKSzVyPUCuNFIxOiEQvF2=	NVz5fXJ{W0GQR1XS
ONS-76	NF[xXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMEKwN\|Yh\|ryP	M3XVcHNCVkeHUh?=
KU812	NXfoO4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7Pe4VKSzVyPUCuNFIxOzlizszN	MYnTRW5ITVJ?
ML-2	M3ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnyTWM2OD1yLkCyNFQ4KM7:TR?=	MmOxV2FPT0WU
HCE-T	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fYbmlEPTB;MD6wNlA6OiEQvF2=	M4fXSXNCVkeHUh?=
NCI-H446	NVftcVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvUdVhmUUN3ME2wMlAzOTF{IN88US=>	MoH2V2FPT0WU
RPMI-6666	M4f2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDuUnVKSzVyPUCuNFIyPDlizszN	NUT4PXl[W0GQR1XS
MOLT-16	NXrQ[Y84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TqVmlEPTB;MD6wNlE2OyEQvF2=	NXjtfokzW0GQR1XS
JiyoyeP-2003	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEKxO\|Yh\|ryP	NEDIbZFUSU6JRWK=
MHH-PREB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4ixVWlEPTB;MD6wNlE6OSEQvF2=	M3nsbnNCVkeHUh?=
MC-CAR	M2\mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfPdG9KSzVyPUCuNFI{OjZizszN	NIrFRodUSU6JRWK=
BC-3	NH7uRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEKzOFQh\|ryP	M161ZnNCVkeHUh?=
KINGS-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS0TWM2OD1yLkCyN\|U2KM7:TR?=	NEjwcZJUSU6JRWK=
PF-382	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn2zTWM2OD1yLkCyN\|c5KM7:TR?=	M4fXbHNCVkeHUh?=
J-RT3-T3-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[2TWM2OD1yLkCyN\|g{KM7:TR?=	MUHTRW5ITVJ?
SF539	NYHoUWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHZc4VnUUN3ME2wMlAzPDBzIN88US=>	MVPTRW5ITVJ?
LB831-BLC	NI\SVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILVdXhKSzVyPUCuNFI1QDVizszN	M1TKRnNCVkeHUh?=
DMS-114	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYL4b2xKUUN3ME2wMlAzPTB{IN88US=>	MnH2V2FPT0WU
LB1047-RCC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfPTWM2OD1yLkCyOVEh\|ryP	MnLiV2FPT0WU
LB771-HNC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ziNGlEPTB;MD6wNlU{PCEQvF2=	MWfTRW5ITVJ?
BB65-RCC	NX3F[5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrlcYdKSzVyPUCuNFI2OzRizszN	NWrwUFdqW0GQR1XS
BV-173	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rPemlEPTB;MD6wNlU2PCEQvF2=	NFOxbHJUSU6JRWK=
ARH-77	MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPjTWM2OD1yLkCyOlAyKM7:TR?=	M1voWHNCVkeHUh?=
IST-MEL1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fTUGlEPTB;MD6wNlYzOyEQvF2=	MULTRW5ITVJ?
NB1	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUKzS4ZsUUN3ME2wMlAzPjh5IN88US=>	MofrV2FPT0WU
EoL-1-cell	NF;kXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3RTWM2OD1yLkCyOlg5KM7:TR?=	MYfTRW5ITVJ?
KY821	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofvTWM2OD1yLkCyOlk4KM7:TR?=	M2fobnNCVkeHUh?=
CMK	NVu3eopST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nEemlEPTB;MD6wNlc{PCEQvF2=	NU\xdI9lW0GQR1XS
NCI-H2126	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEK3Olgh\|ryP	M2nBZ3NCVkeHUh?=
NCI-H526	NVO1ZnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTJUllmUUN3ME2wMlAzQDlzIN88US=>	MXTTRW5ITVJ?
COLO-684	M2P5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nDUWlEPTB;MD6wNlkxQCEQvF2=	NUDzR3FsW0GQR1XS
NCI-H747	NGD6Z\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\UOFhKSzVyPUCuNFI6OzNizszN	MV3TRW5ITVJ?
JAR	M4PnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fIfmlEPTB;MD6wNlk1PiEQvF2=	MX3TRW5ITVJ?
MEG-01	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMEK5O\|gh\|ryP	M176dHNCVkeHUh?=
MONO-MAC-6	NGf4eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLKSJJKSzVyPUCuNFMxOjNizszN	MmnyV2FPT0WU
IST-SL1	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjXTWM2OD1yLkCzNFQzKM7:TR?=	NYX0[2JnW0GQR1XS
CPC-N	NH3SenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPMPWRKSzVyPUCuNFMxPzlizszN	M3rnNXNCVkeHUh?=
NCI-H1963	NVXYd5l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHZTWM2OD1yLkCzNVMyKM7:TR?=	M{PPO3NCVkeHUh?=
K052	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn6S2V2UUN3ME2wMlA{OjR5IN88US=>	MV\TRW5ITVJ?
KM-H2	M3[4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEOzNFch\|ryP	M2G4ZXNCVkeHUh?=
TE-12	NFLrZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzIZoYyUUN3ME2wMlA{OzB7IN88US=>	NUK1b4xUW0GQR1XS
TK10	M2K1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHDTWM2OD1yLkCzN\|U3KM7:TR?=	Mn[xV2FPT0WU
NMC-G1	NU\iRZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLJTWM2OD1yLkCzOFUzKM7:TR?=	M2PiO3NCVkeHUh?=
no-11	M1HzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT6TWM2OD1yLkCzOFc5KM7:TR?=	M2CwUXNCVkeHUh?=
NCI-H524	M13vUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTZTWM2OD1yLkCzOVI6KM7:TR?=	M4nFbnNCVkeHUh?=
MHH-CALL-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSxSWVyUUN3ME2wMlA{PTZ{IN88US=>	MX7TRW5ITVJ?
GB-1	NWCzNG53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEO2JO69VQ>?	NYey[YEyW0GQR1XS
OPM-2	NH7rVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\DS4dyUUN3ME2wMlA{Pjd\|IN88US=>	MkHMV2FPT0WU
RH-1	NEfu[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\xTWM2OD1yLkCzPFE6KM7:TR?=	M3O2UnNCVkeHUh?=
NCI-H64	NH7w[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLLTWM2OD1yLkCzPFU4KM7:TR?=	M4XtUXNCVkeHUh?=
EVSA-T	M3qyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEO5NlMh\|ryP	M4DvPHNCVkeHUh?=
KARPAS-299	NEX2TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33Jd2lEPTB;MD6wN\|k5KM7:TR?=	M3XvfXNCVkeHUh?=
MZ7-mel	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DwN2lEPTB;MD6wOFA1KM7:TR?=	NX7sOlBIW0GQR1XS
LB373-MEL-D	M4nucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMESxNFUh\|ryP	NGm4NWJUSU6JRWK=
HEL	NIjweFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTkTWM2OD1yLkC0NVQh\|ryP	MmP1V2FPT0WU
SW872	NWS2XXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLBOohlUUN3ME2wMlA1OjFizszN	MWHTRW5ITVJ?
DU-4475	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;TfZNKSzVyPUCuNFQzPDRizszN	NYDUSGRJW0GQR1XS
IST-SL2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzBXVRKSzVyPUCuNFQzPzVizszN	M37nTnNCVkeHUh?=
NCI-H82	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fYZWlEPTB;MD6wOFMxPyEQvF2=	NGfHWXBUSU6JRWK=
LC4-1	NEn6[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMESzOVEh\|ryP	NXX5bYtxW0GQR1XS
HDLM-2	NW\Hd5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG3TWM2OD1yLkC0N\|kzKM7:TR?=	NYXweIx2W0GQR1XS
MMAC-SF	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULwToR6UUN3ME2wMlA1PTN2IN88US=>	M4HsNnNCVkeHUh?=
L-540	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PIfGlEPTB;MD6wOFY{QSEQvF2=	M17H[3NCVkeHUh?=
MZ2-MEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLQfoxMUUN3ME2wMlA1PzR{IN88US=>	MXHTRW5ITVJ?
LU-134-A	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XrOGlEPTB;MD6wOFc4OyEQvF2=	MULTRW5ITVJ?
UACC-257	NWm2cWt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH1TWM2OD1yLkC0PFQ6KM7:TR?=	M{TacXNCVkeHUh?=
NCI-H1581	NUjuVYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m1dWlEPTB;MD6wOFk2OyEQvF2=	NH\VVFdUSU6JRWK=
NB17	M2nHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXZVmMyUUN3ME2wMlA1QTd7IN88US=>	M{PhO3NCVkeHUh?=
SBC-1	M3W1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHvbZZKSzVyPUCuNFUxPDJizszN	NFnMd2FUSU6JRWK=
TALL-1	M3rhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7PUmJKSzVyPUCuNFUxPDVizszN	M4iyWnNCVkeHUh?=
NCI-H1304	Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnXTWM2OD1yLkC1NlA5KM7:TR?=	M17INnNCVkeHUh?=
NEC8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jsbmlEPTB;MD6wOVI5PiEQvF2=	MUjTRW5ITVJ?
CAL-148	NG\wS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfGZoZKSzVyPUCuNFU1OzlizszN	MkDIV2FPT0WU
CGTH-W-1	M4PYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HFZWlEPTB;MD6wOVQ1QSEQvF2=	NFPnfo1USU6JRWK=
NCI-H889	M{P5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjTTWM2OD1yLkC1OVkzKM7:TR?=	NEftOo9USU6JRWK=
GR-ST	NHXz[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PUNWlEPTB;MD6wOVYzOSEQvF2=	NIXtPYdUSU6JRWK=
KARPAS-422	NGCybGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLHTYNKSzVyPUCuNFU3PSEQvF2=	MX;TRW5ITVJ?
RPMI-8866	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnKd3A3UUN3ME2wMlA2PzF{IN88US=>	M3fj[HNCVkeHUh?=
SCLC-21H	M2Hrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP6TWM2OD1yLkC1PFg1KM7:TR?=	NFnvbYpUSU6JRWK=
COR-L88	M3\IUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1P4c2lEPTB;MD6wOVkzPyEQvF2=	M2[3SHNCVkeHUh?=
LU-139	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO2eGVKSzVyPUCuNFU6QDZizszN	MmL3V2FPT0WU
SF126	NETaVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{i3eGlEPTB;MD6wOlE{OyEQvF2=	NYPiVms3W0GQR1XS
NCI-H1882	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnxNoJKSzVyPUCuNFY1OjRizszN	NGH3eYdUSU6JRWK=
EW-24	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PwdGlEPTB;MD6wOlQ5OyEQvF2=	M37zUnNCVkeHUh?=
CP67-MEL	NXPM[XZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwME[4NUDPxE1?	NGPSSYVUSU6JRWK=
DG-75	NH\jS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\SeIh2UUN3ME2wMlA3QDl7IN88US=>	MYDTRW5ITVJ?
LOXIMVI	NYTYR4V5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjMTWM2OD1yLkC3NFI5KM7:TR?=	NGq0[YFUSU6JRWK=
HH	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnPTWM2OD1yLkC3NVU4KM7:TR?=	NELrfXNUSU6JRWK=
K5	M33KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rQXGlEPTB;MD6wO\|IzPiEQvF2=	M{\RW3NCVkeHUh?=
EC-GI-10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\abZM6UUN3ME2wMlA4OjV5IN88US=>	NXP6ZlV1W0GQR1XS
SK-N-DZ	NVP5RlVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEn1RZZKSzVyPUCuNFc{ODdizszN	MYrTRW5ITVJ?
A3-KAW	NH7UO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XsOWlEPTB;MD6wO\|M2OSEQvF2=	Mlz0V2FPT0WU
MLMA	NX75T2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEe0OlUh\|ryP	Mmj2V2FPT0WU
LB996-RCC	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfETWM2OD1yLkC3O\|A4KM7:TR?=	NXjMNZRTW0GQR1XS
OS-RC-2	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXH0WZBtUUN3ME2wMlA4PzR6IN88US=>	M4m0eHNCVkeHUh?=
CTB-1	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLYZo1DUUN3ME2wMlA4QDFizszN	M3vXWXNCVkeHUh?=
IST-MES1	NVvncFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMEe5NVIh\|ryP	NYe2UnFVW0GQR1XS
LS-1034	NX[wO3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrVTWM2OD1yLkC4NFM2KM7:TR?=	MlvCV2FPT0WU
HT	NEXE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XDN2lEPTB;MD6wPFA5PiEQvF2=	NFS0VGdUSU6JRWK=
NCI-H2141	NYLhXYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL5Z3RKSzVyPUCuNFgyKM7:TR?=	M1PyU3NCVkeHUh?=
LB2518-MEL	NUDFW\|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrhTWM2OD1yLkC4NVQyKM7:TR?=	M2XiSnNCVkeHUh?=
GI-ME-N	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofCTWM2OD1yLkC4OFUzKM7:TR?=	M17FN3NCVkeHUh?=
TGW	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMEi2NFch\|ryP	MW\TRW5ITVJ?
SK-NEP-1	M{TpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfDTWM2OD1yLkC4OlQyKM7:TR?=	NIHtbVVUSU6JRWK=
NOMO-1	NF63ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT1TWM2OD1yLkC5Nlc2KM7:TR?=	NYroSYR[W0GQR1XS
ES6	M37qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnPTWM2OD1yLkC5OVg6KM7:TR?=	NETtSlNUSU6JRWK=
NCI-H209	M3;hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPVTWM2OD1yLkC5O\|g3KM7:TR?=	M2DG[XNCVkeHUh?=
GAK	NWn4N5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHjXYdKSzVyPUCuNVAyPiEQvF2=	NGO4c5FUSU6JRWK=
BC-1	M2j4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Lwe2lEPTB;MD6xNFM3OSEQvF2=	NHj2Z49USU6JRWK=
KLE	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nyd2lEPTB;MD6xNFQ1OyEQvF2=	M1nNVXNCVkeHUh?=
EW-3	NGG4ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrhSWlbUUN3ME2wMlExQThizszN	M{D1SXNCVkeHUh?=
NKM-1	M1X6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMUGxJO69VQ>?	NYDhRpZyW0GQR1XS
D-336MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTI[nBKSzVyPUCuNVEzPDRizszN	M3Tu[HNCVkeHUh?=
NB69	M3u4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\NWmlEPTB;MD6xNVMxOSEQvF2=	M1T1WXNCVkeHUh?=
D-263MG	NYOyZ\|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nHVWlEPTB;MD6xNVcyOiEQvF2=	MkS4V2FPT0WU
KP-N-YS	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PZXGlEPTB;MD6xNlI6OSEQvF2=	MWTTRW5ITVJ?
NCI-H1155	M{joUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMUK1OVgh\|ryP	MXLTRW5ITVJ?
BOKU	M1TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2wSohKSzVyPUCuNVI2PzlizszN	MmL4V2FPT0WU
LAMA-84	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnQN3VyUUN3ME2wMlEzQTlizszN	M3j0WXNCVkeHUh?=
Raji	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHPVJBKSzVyPUCuNVMyOTdizszN	NX;vZW1IW0GQR1XS
LU-65	NFq1epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PZWGlEPTB;MD6xN\|MxPyEQvF2=	NWPDeJlMW0GQR1XS
NCI-H187	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1uzdmlEPTB;MD6xN\|kzPCEQvF2=	M3jESXNCVkeHUh?=
GCIY	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnPfJM4UUN3ME2wMlE1QTBzIN88US=>	NWTqWZZRW0GQR1XS
NCI-H2107	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHKxW4JKSzVyPUCuNVUxQCEQvF2=	NYLYXFY1W0GQR1XS
NCI-H1522	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMUWyOlYh\|ryP	M{\q[HNCVkeHUh?=
NB6	M4\GfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTUb\|hoUUN3ME2wMlE2PjJ\|IN88US=>	M1zwZXNCVkeHUh?=
EM-2	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrqc3FKSzVyPUCuNVU4ODZizszN	MoTzV2FPT0WU
HCC2218	M4DaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVOyRmVqUUN3ME2wMlE2QThizszN	MnizV2FPT0WU
NCI-H748	M1m2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTDTWM2OD1yLkG2N\|c3KM7:TR?=	NUjZR2FqW0GQR1XS
MS-1	NYW3OHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LDc2lEPTB;MD6xOlU{PyEQvF2=	NYnNeoV7W0GQR1XS
NB5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlKwTWM2OD1yLkG2OVk4KM7:TR?=	NH3LVFlUSU6JRWK=
OMC-1	NGLXVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHqb3JwUUN3ME2wMlE3Pjh6IN88US=>	NIqxZWpUSU6JRWK=
NCI-H345	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrKTWM2OD1yLkG2PVI5KM7:TR?=	M3;URnNCVkeHUh?=
L-428	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\NeWhKUUN3ME2wMlE3QTR3IN88US=>	M2TUVHNCVkeHUh?=
SCH	M3foXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvhUlFmUUN3ME2wMlE5Pjh3IN88US=>	NIXaOGxUSU6JRWK=
NCI-H1417	NF3YR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfufpdKSzVyPUCuNVkzOjdizszN	MkDTV2FPT0WU
COLO-320-HSR	NVK2fYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnNWJJFUUN3ME2wMlE6PTN{IN88US=>	NEHWWJRUSU6JRWK=
BT-474	M{TVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7ETWM2OD1yLkKwPFkzKM7:TR?=	NXmxZmVkW0GQR1XS
GDM-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXxZWI3UUN3ME2wMlIyQTdzIN88US=>	MkH6V2FPT0WU
NCI-H2196	M3zZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFqyWIpKSzVyPUCuNlIzOzVizszN	NH3VPGdUSU6JRWK=
KP-N-RT-BM-1	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\Cfm5KSzVyPUCuNlI{PDlizszN	M1vtS3NCVkeHUh?=
KNS-81-FD	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HN[WlEPTB;MD6yNlk2QCEQvF2=	NHPDeJFUSU6JRWK=
COLO-668	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLoVnc3UUN3ME2wMlI{Pjd3IN88US=>	Mnr0V2FPT0WU
C2BBe1	NUTwUpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHMTWM2OD1yLkK2O\|Q4KM7:TR?=	NHjvN4VUSU6JRWK=
Ramos-2G6-4C10	NGrhb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf4SmlKSzVyPUCuNlY6PTRizszN	M1\0VHNCVkeHUh?=
CAS-1	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;HZWlEPTB;MD6yO\|A6PiEQvF2=	NIfkeopUSU6JRWK=
GOTO	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvCTWM2OD1yLkK3PFk1KM7:TR?=	NHzxVIdUSU6JRWK=
LP-1	NHW0RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPK[JRKSzVyPUCuNlgxPTdizszN	NWPOZYcxW0GQR1XS
NCI-SNU-1	MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTwXGRPUUN3ME2wMlI6PDJ{IN88US=>	MWnTRW5ITVJ?
EB-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVznNGlwUUN3ME2wMlI6QTd7IN88US=>	NIPvfXBUSU6JRWK=
MHH-NB-11	NGe0dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLSTJFKSzVyPUCuN\|A1ODJizszN	MoHTV2FPT0WU
SK-N-FI	NIracG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P0SWlEPTB;MD6zNVY6OiEQvF2=	NGTBZldUSU6JRWK=
HCC2157	NUjLXXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;3PFhDUUN3ME2wMlM{QTF\|IN88US=>	NUm2[phwW0GQR1XS
SIMA	M2jUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwM{S1PFEh\|ryP	MVTTRW5ITVJ?
MDA-MB-134-VI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3O[nBSUUN3ME2wMlM3QTJ6IN88US=>	NH\lbGVUSU6JRWK=
NCI-H1694	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17FWGlEPTB;MD6zO{DPxE1?	NIG0O4RUSU6JRWK=
EHEB	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkL0TWM2OD1yLkO5NFg2KM7:TR?=	MmPKV2FPT0WU
U-266	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwM{m4OFYh\|ryP	MX7TRW5ITVJ?
LC-1F	Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r4fWlEPTB;MD60N\|c3PSEQvF2=	MWHTRW5ITVJ?
SHP-77	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4O3WWlEPTB;MD60O\|g2PSEQvF2=	MVHTRW5ITVJ?
LS-513	NEfiWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHE[5hKSzVyPUCuOFk{ODdizszN	M4XDOHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	- Collapse Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[4]	- Collapse Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

- Collapse

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

- Collapse

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

- Collapse

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000906	Not yet recruiting	Drug: NAB paclitaxel\|Drug: Cisplatin	Peritoneal Carcinomatosis	University Hospital Geneva	September 2019	Phase 1
NCT04046887	Not yet recruiting	Drug: Lonsurf\|Drug: Gemcitabine\|Drug: Nab-Paclitaxel	Pancreatic Cancer\|Pancreatic Ductal Adenocarcinoma	Patrick Joseph Loehrer Sr.\|Indiana University\|Taiho Oncology Inc.	August 2019	Phase 1
NCT03779464	Recruiting	Drug: S1 or Gemcitabine	Pancreatic Cancer\|Nab-paclitaxel\|Gemcitabine\|S1	Wuhan Union Hospital China	August 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 120 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 120 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)